Showing results (171-180 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|June 13, 2021
Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancerK Kato, T Masuishi, K Fushiki, et al.
ESMO Open|June 17, 2022
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancerB Tombal, C N Sternberg, M Hussain, et al.
ESMO Open|May 13, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancerS-A Im, A Gennari, Y H Park, et al.
ESMO Open|April 5, 2021
Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgeryHoussein El Hajj, M Vanseymortier, D Hudry, et al.
ESMO Open|July 16, 2020
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised studyMark Rosenthal, Paul M Clement, Mario Campone, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
ESMO Open|March 29, 2021
Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancerW Yao, X Zhao, Y Gong, et al.
ESMO Open|August 5, 2020
Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanomaEmilie Le Rhun, Fabian Wolpert, Maud Fialek, et al.
ESMO Open|August 21, 2020
Brain microenvironment-driven resistance to immune and targeted therapies in acral melanomaRebecca Jane Lee, Garima Khandelwal, Franziska Baenke, et al.
ESMO Open|August 21, 2020
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, Georgia-Angeliki Koliou, Athanassios Vozikis, et al.
Pageof 184